Home Newsfeeds Apexigen Q3 EPS $(0.41) Misses $(0.38) Estimate

Apexigen Q3 EPS $(0.41) Misses $(0.38) Estimate

Apexigen (NASDAQ:APGN) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.89 percent.

byBenzinga Newsdesk

November 15, 2022

1 minute read

Apexigen (NASDAQ:APGN) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.89 percent.

Floki Outshines Dogecoin, Shiba Inu With 3% Spike On New Exchange Listing

By Mehab Qureshi

March 1, 1:54 AM

Floki (CRYPTO: FLOKI) is up 3% in the last 24 hours, outperforming the top five meme coins by market capitalization.

$DOGE

What’s Going On With Chinese EV Maker XPeng Stock Today?

By Nabaparna Bhattacharya

May 15, 7:24 AM

XPeng shares are up in premarket trading as the company reportedly plans to use BYD batteries for its new Mona sub-brand, aiming for a June debut of its first A-class compact electric sedan priced between RMB 100,000 and RMB 150,000.

BYDDF

FDA Approves Merck’s Blockbuster Cancer Drug For Type Of Gastric Cancer

By Vandana Singh

November 17, 9:42 AM

The FDA has approved Merck & Co Inc's (NYSE: MRK) Keytruda, an anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)

MRK

Why Sea Limited Shares Are Soaring Today

By Adam Eckert

November 15, 10:30 AM

Sea Limited (NYSE: SE) shares are trading higher Tuesday after the company reported better-than-expected financial results.

Apexigen Q3 EPS $(0.41) Misses $(0.38) Estimate

Related Posts

Floki Outshines Dogecoin, Shiba Inu With 3% Spike On New Exchange Listing

What’s Going On With Chinese EV Maker XPeng Stock Today?

FDA Approves Merck’s Blockbuster Cancer Drug For Type Of Gastric Cancer

Why Sea Limited Shares Are Soaring Today